TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02513836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-education intervention
Description: All study participants will be tested with a questionnaire (POEM; Patient Opioids Education Measurement) on their opioid knowledge during 1st visit at the pain clinic.

Intervention type: OTHER
Group type: OTHER
Intervention: Post-education intervention
Description: All study participants will be educated on opioids via an education sheet, pamphlet and video from the Institute for Safe Medication Practices (ISMP) Canada. The questionnaire (POEM) will be tested again after this education on opioid knowledge on the same day.
Study: NCT02657148

Intervention type: DRUG
Intervention: Nexplanon (etonogestrel contraceptive implant)
Description: Nexplanon is a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel indicated for postpartum contraceptive use by women to prevent pregnancy. Nexplanon is designed to be effective for 3 years.

Intervention type: DRUG
Intervention: Standard postpartum contraceptive care
Description: Condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at \> 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time \> 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time \> 6 weeks after delivery.
Study: NCT03179878

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1020
Description: Investigational Product
Study: NCT00329043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Agonist
Description: Intramuscular injection either monthly for 3 months or in a single 3-month dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: 25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Radical prostatectomy after completion of Sunitinib and LHRH agonist.
Study: NCT03234634

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovascular thrombectomy
Description: Intervention description : Group 1: patients with good collateral, Group 2: patient with poor collateral~1. Group 1 patients (good collateral group) will receive endovascular thrombectomy using stent retriever, aspiration catheter, or both, if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.~2. Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
Study: NCT00897026

Intervention type: DRUG
Intervention: cyclophosphamide

Intervention type: DRUG
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Intervention: paclitaxel

Intervention type: GENETIC
Intervention: fluorescence in situ hybridization

Intervention type: OTHER
Intervention: immunohistochemistry staining method
Study: NCT01470157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 5mg/kg as oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline (placebo) in addition to Midazolam 0.5mg/kg as oral suspension
Study: NCT02170064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 (Eslicarbazepine acetate)
Description: Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 (Eslicarbazepine acetate)
Description: Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 (Eslicarbazepine acetate)
Description: Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route
Study: NCT04211363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast 0.3% cream
Description: Roflumilast 0.3% cream for topical application.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Vehicle cream for topical application.
Study: NCT04850326

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AP green tea extract
Description: single intake of AP green tea extract
Study: NCT04660734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractures of the posterior structures of the acetabulum treated by fixation using the Kocher-Langenbeck approach.
Description: Fracture fixation of posterior structures of acetabulum by using the surgical procedure of Kocher-Langenbeck approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractures of the posterior structures of the acetabulum treated by fixation using the Kocher-Langenbeck approach.
Description: Fracture fixation of posterior structures of acetabulum by using the surgical procedure of Kocher-Langenbeck approach
Study: NCT02144467

Intervention type: DEVICE
Intervention: MRI
Description: fMRI, sMRI, ASL and DTI
Study: NCT01486888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 30
Description: Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin 30
Description: Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
Study: NCT00872300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHA-739358
Description: Weekly IV infusion for 3 consecutive weeks in a 4-week cycle
Study: NCT03498417

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum antibodies against the IGF-1R
Description: Measurement of antibodies against the IGF-1R in serum samples by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum antibodies against the IGF-1R
Description: Measurement of antibodies against the IGF-1R in serum samples by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum antibodies against the IGF-1R
Description: Measurement of antibodies against the IGF-1R in serum samples by ELISA
Study: NCT03589105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab 300 mg
Description: Two doses of 300 mg infusion administered 14 days apart.
Study: NCT01812057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8 mg IV (as a one time dose)
Study: NCT03589105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab 600 mg
Description: A single does of 600 mg infusion administered 24 weeks after the initial dose.
Study: NCT03629392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low met/cys diet
Description: Dietary intervention with low contents of methionine and cysteine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate met/cys diet
Description: Dietary intervention with moderate contents of methionine and cysteine
Study: NCT01812057

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9% -5 ml
Study: NCT03832738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTE-451 Tablets
Description: Active drug tablets containing JTE-451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTE-451 Tablets
Description: Active drug tablets containing JTE-451

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo tablets matching in appearance to the active drug tablets
Study: NCT01758146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg once daily for 5 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letroz, Femara, Letronat
Study: NCT00466973

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry bipolar radiofrequency (RF) clamp
Description: Specified device used for ablation during standard surgical procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unipolar microwave antenna
Description: Specified device used for ablation during standard surgical procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unipolar cryothermic probe
Description: Specified device used for ablation during standard surgical procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigated unipolar RF antenna
Description: Specified device used for ablation during standard surgical procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigated bipolar RF clamp
Description: Specified device used for ablation during standard surgical procedure
Study: NCT03819309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transvaginal drainage
Description: evacuation of the TOA will be done by ultrasound-guided transvaginal puncture under simple sedation or under general anesthesia if necessary

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy
Description: TOA will be evacuated by coelioscopy under general anesthesia
Study: NCT03377660

Intervention type: OTHER
Intervention: Clinical treatment
Description: Patients undergo clinical treatment as indicated, they are studied before and after.

Intervention type: OTHER
Intervention: Clinical treatment
Description: Patients undergo clinical treatment as indicated, they are studied before and after.
Study: NCT03140618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The light and environment project in psychiatric inpatient care
Description: Complete rebuilding of a hospital ward.~The ward layout is remodeled and different devices and services are installed such as light, sound, and color settings, increased opportunities for physical activity, social harmony, privacy, peace, and quiet. A comfort room and a activity room will be built.
Study: NCT00466973

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hi-intensity focused ultrasound wand
Description: Specified device used for ablation during standard surgical procedure
Study: NCT05595746

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implant placement
Description: In dental implant placement surgery, first of all, intraoral infiltrative anesthesia is applied to the area. After the crestal incision, the buccal flap is elevated to full thickness. Vertical mucosal height is measured with a William type standard periodontal probe. The palatal/lingual flap is then elevated to full thickness. The implant is placed at different levels with the standard protocol determined by the manufacturer. Study groups are determined by the placement levels of the implants and the vertical mucosal height measurement values. After the implants are placed, the flap is closed primarily.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implant placement
Description: In dental implant placement surgery, first of all, intraoral infiltrative anesthesia is applied to the area. After the crestal incision, the buccal flap is elevated to full thickness. Vertical mucosal height is measured with a William type standard periodontal probe. The palatal/lingual flap is then elevated to full thickness. The implant is placed at different levels with the standard protocol determined by the manufacturer. Study groups are determined by the placement levels of the implants and the vertical mucosal height measurement values. After the implants are placed, the flap is closed primarily.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implant placement
Description: In dental implant placement surgery, first of all, intraoral infiltrative anesthesia is applied to the area. After the crestal incision, the buccal flap is elevated to full thickness. Vertical mucosal height is measured with a William type standard periodontal probe. The palatal/lingual flap is then elevated to full thickness. The implant is placed at different levels with the standard protocol determined by the manufacturer. Study groups are determined by the placement levels of the implants and the vertical mucosal height measurement values. After the implants are placed, the flap is closed primarily.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implant placement
Description: In dental implant placement surgery, first of all, intraoral infiltrative anesthesia is applied to the area. After the crestal incision, the buccal flap is elevated to full thickness. Vertical mucosal height is measured with a William type standard periodontal probe. The palatal/lingual flap is then elevated to full thickness. The implant is placed at different levels with the standard protocol determined by the manufacturer. Study groups are determined by the placement levels of the implants and the vertical mucosal height measurement values. After the implants are placed, the flap is closed primarily.
Study: NCT02588885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-sensitive Care
Description: Psychological intervention~1. education~2. empowerment~3. desensitization~4. relaxation tools~Physical therapy intervention~1. techniques to address muscular tension~2. empowerment~3. comfort~4. encouragement of trauma-related coping skills
Study: NCT00048984

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02378597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Resiliency Intervention
Description: 4 hour behavioral session including education in the relaxation response, education about stress and allostatic load, cognitive skills building, review of difficult encounters with patients.
Study: NCT04108923

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure
Description: the vessel sealing device ( ligasure covidien ) which seals vessels by fusing the inner layers of the vessel wall

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional vessel ligation
Description: Conventional vessel ligation either tying and /or clipping of blood vessels
Study: NCT02481557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxalate Salt Solution
Description: Applied by dentist
Study: NCT02647684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Directed Triple P
Description: 10 Week Triple P Self directed workbook
Study: NCT04546100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal-Infant Exercise Program
Description: Maternal-Infant Exercise Program can be divided into three videos stages. As time progresses during the three months, the parent-child exercise videos provided will have stronger intensity. The content includes general post-natal exercises (e.g., baby Lying on the mother's bed, raising legs or back of hands exercises, breast exercises; neck exercises; pelvic swinging exercises), aerobic exercises (e.g. walking with strollers, walking with baby on back), core exercises (e.g. kneeling balance, kneeling Push ups, stick exercises, modified side stick exercises) and hip and leg exercises (such as donkey kicks, side lifts), etc., with relaxing music during exercise.
Study: NCT01819324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeting the Teachable Moment
Description: TTMI material (every other week for 4 months)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Lifestyle Management
Description: SLM material (every other week for 4 months)
Study: NCT02350582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation eCUIDATE system
Description: Resistence and endurance exercise adapted to individual requeriment during chemotherapy
Study: NCT00754013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept (Donepezil hydrochloride)
Description: All subjects will start with a dose of 1.25 mg/day (1.25 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil.~All doses will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects will start with a dose of 1.25 mg/day (1.25 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) placebo.~All doses will be administered orally.
Study: NCT00131638

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
Study: NCT04056039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
Study: NCT02825368

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR
Description: 0.5 mL, subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tdap
Description: 0.5 mL, intramuscular

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diphtherinum®

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pertussinum®

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tetanotxicum®

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morbilinum®

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ourlianum®

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: 0.5 mL, intramuscular

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile saline
Description: 0.5 mL, intramuscular

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pellets

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar pellets
Study: NCT06414850

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Animal Assisted Therapy (AAT)
Description: A structured AAT program and pharmacological treatment in Experimental group. The same structured program without therapy dog and pharmacological treatment in Control group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal Assisted Therapy (AAT)
Description: A structured AAT program and pharmacological treatment in Experimental group. The same structured program without therapy dog and pharmacological treatment in Control group.
Study: NCT01337635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks
Study: NCT00989937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 20 IU BID or 40 IU BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: 20 IU BID or 40 IU BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 20 IU BID or 40 IU BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 IU BID or 40 IU BID
Study: NCT02135042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study: NCT03026907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alitretinoin
Description: Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Oral azathioprine tablets twice daily in a dose of 1.5 or 2.5mg/kg/day, depending on the thiopurine methyltransferase (TPMT) activity.
Study: NCT03182894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA)
Description: Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
Study: NCT04186598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP mask system
Description: Intervention group will receive 15cm of H2O of positive end expiratory pressure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nifedipine 30 MG
Description: All participants will receive this intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 MG
Description: All participants will receive this intervention

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CPAP mask system without PEEP
Description: Placebo group will receive high flow oxygen via altered CPAP mask system without providing any positive end expiratory pressure
Study: NCT01859767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I]MNI-672 SPECT
Description: Subjects will be dosed by intravenous injection to a target dose of 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) I-123 MNI-672 prior to the SPECT scan.
Study: NCT04462016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calamansi
Description: 250 ml of a commercially sourced calamansi drink

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 75 g of glucose dissolved in 250 ml of drinking water
Study: NCT04900909

Intervention type: DEVICE
Intervention: Aortic Valve Replacement
Description: Surgical replacement of aortic valves

Intervention type: DEVICE
Intervention: Aortic Valve Replacement
Description: Surgical replacement of aortic valves